Stryker Co. (NYSE:SYK) Shares Acquired by AMI Investment Management Inc.

AMI Investment Management Inc. boosted its holdings in Stryker Co. (NYSE:SYK) by 11.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,345 shares of the medical technology company’s stock after purchasing an additional 1,096 shares during the quarter. Stryker makes up 1.2% of AMI Investment Management Inc.’s portfolio, making the stock its 26th biggest holding. AMI Investment Management Inc.’s holdings in Stryker were worth $3,725,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in SYK. Dale Q Rice Investment Management Ltd acquired a new position in shares of Stryker during the 4th quarter valued at about $587,000. PFW Advisors LLC acquired a new position in Stryker during the fourth quarter worth approximately $1,350,000. Parnassus Investments LLC purchased a new position in Stryker during the third quarter worth approximately $762,798,000. Baltimore Washington Financial Advisors Inc. boosted its holdings in shares of Stryker by 2.4% in the 3rd quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company’s stock valued at $24,089,000 after purchasing an additional 1,554 shares during the last quarter. Finally, Sivik Global Healthcare LLC increased its holdings in shares of Stryker by 8.0% during the 3rd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock worth $9,754,000 after buying an additional 2,000 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Up 0.6 %

Shares of NYSE SYK opened at $383.91 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average price is $375.51 and its two-hundred day moving average price is $358.98. Stryker Co. has a 52-week low of $307.23 and a 52-week high of $398.20. The stock has a market capitalization of $146.35 billion, a P/E ratio of 41.15, a PEG ratio of 2.51 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.46 EPS. On average, analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker’s payout ratio is 36.01%.

Analyst Ratings Changes

A number of research firms have issued reports on SYK. Wells Fargo & Company boosted their price target on Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. BTIG Research raised their price target on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. increased their price objective on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. JMP Securities restated a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Finally, StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Thursday, January 9th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Insider Activity at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.50% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.